Patents by Inventor Axel Rethwilm

Axel Rethwilm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120141440
    Abstract: The disclosure of the present application provides foamyvirus vectors, as well as methods and kits involving the same. In at least one embodiment, a plurality of recombinant vectors comprises an expression sequence encoding at least one component of a foamyvirus particle, wherein at least one codon of the expression sequence is optimized for expression in homo sapiens.
    Type: Application
    Filed: March 26, 2010
    Publication date: June 7, 2012
    Inventors: Axel Rethwilm, Dirk Lindemann, Helmut Hanenberg, Wade D. Clapp
  • Patent number: 6703226
    Abstract: The invention concerns constructs for the expression of a protein comprising at least a modified FV envelope protein, the protein so obtained as well as the complementation cell line permitting the production of pseudotyped viral particle. It also concerns pharmaceutical composition comprising said particles and a method for treating a disease.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: March 9, 2004
    Assignee: Transgene S.A.
    Inventors: Dirk Lindemann, Axel Rethwilm
  • Publication number: 20010031257
    Abstract: The present invention relates to the preparation of novel vector systems which are generated by in-vitro recombination, using gene technology, of nucleic acids from foamy virus species and of exogenous nucleic acid, and are produced by suitable host cells or by recombinantly altered packaging cell lines. The recombinant preparation of particularly suitable packaging cell lines is likewise a constituent of this invention. The invention is distinguished by the safe and efficient transfer by foamy virus vectors of therapeutic and other genes into eukaryotic cells.
    Type: Application
    Filed: September 15, 1995
    Publication date: October 18, 2001
    Inventors: VOLKER T. MEULEN, AXEL RETHWILM
  • Patent number: 6277601
    Abstract: The invention concerns constructs for the expression of a protein comprising at least a modified FV envelope protein, the protein so obtained as well as the complementation cell line permitting the production of pseudotyped viral particle. It also concerns pharmaceutical composition comprising said particles and a method for treating a disease.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: August 21, 2001
    Assignee: Transgene S.A.
    Inventors: Axel Rethwilm, Dirk Lindemann, Arend Jan Winter
  • Patent number: 6274722
    Abstract: The invention concerns constructs for the expression of a protein comprising at least a modified FV envelope protein, the protein so obtained as well as the complementation cell line permitting the production of pseudotyped viral particle. It also concerns pharmaceutical composition comprising said particles and a method for treating a disease.
    Type: Grant
    Filed: July 17, 2000
    Date of Patent: August 14, 2001
    Assignee: Transgene S.A.
    Inventors: Dirk Lindemann, Axel Rethwilm
  • Patent number: 6150138
    Abstract: The invention concerns constructs for the expression of a protein comprising at least a modified FV envelope protein, the protein so obtained as well as the complementation cell line permitting the production of pseudotyped viral particle. It also concerns pharmaceutical composition comprising said particles and a method for treating a disease.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: November 21, 2000
    Assignee: Transgene S.A.
    Inventors: Dirk Lindemann, Axel Rethwilm
  • Patent number: 6111087
    Abstract: The invention concerns constructs for the expression of a protein comprising at least a modified FV envelope protein, the protein so obtained as well as the complementation cell line permitting the production of pseudotyped viral particle. It also concerns pharmaceutical composition comprising said particles and a method for treating a disease.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: August 29, 2000
    Assignee: Transgene S.A.
    Inventors: Axel Rethwilm, Dirk Lindemann, Arend Jan Winter
  • Patent number: 5929222
    Abstract: The invention concerns constructs for the expression of a protein comprising at least a modified FV envelope protein, the protein so obtained as well as the complementation cell line permitting the production of pseudotyped viral particle. It also concerns pharmaceutical composition comprising said particles and a method for treating a disease.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: July 27, 1999
    Assignee: Transgene S.A.
    Inventors: Dirk Lindemann, Axel Rethwilm
  • Patent number: 5646032
    Abstract: The present invention relates to the preparation of novel vector systems which are generated by in-vitro recombination, using gene technology, of nucleic acids from foamy virus species and of exogenous nucleic acid, and are produced by suitable host cells or by recombinantly altered packaging cell lines. The recombinant preparation of particularly suitable packaging cell lines is likewise a constituent of this invention. The invention is distinguished by the safe and efficient transfer by foamy virus vectors of therapeutic and other genes into eukaryotic cells.
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: July 8, 1997
    Assignee: Bayer Aktiengesellschaft
    Inventors: Volker ter Meulen, Axel Rethwilm